Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Peripheral neuropathy induced by microtubule-stabilizing agents.

James J Lee1, Sandra M Swain

  • 1Breast Cancer Section, Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20889-5015, USA.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|April 1, 2006
PubMed
Summary

Microtubule-stabilizing agents (MTSAs) effectively treat cancer but can cause severe neuropathy in up to 30% of patients. Early recognition and supportive care are crucial for managing this common chemotherapy side effect.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Growing Up with Parents Who Smoke: Genetic and Environmental Effects on Offspring Substance Use and Externalizing Psychopathology From a 20-Year Minnesota Study of Adoptive Families.

Behavior genetics·2026
Same author

Durable Lessons on Intelligence from Twin and Adoption Research.

Behavior genetics·2026
Same author

AI-powered and manual assessment of tumor-infiltrating lymphocytes in early HER2-positive breast cancer in NSABP B-41.

NPJ breast cancer·2026
Same author

Sex-based prognosis in industry-sponsored advanced solid tumor trials: an individual participant data meta-analysis of survival and adverse events.

Journal of the National Cancer Institute·2026
Same author

More than <math><mrow><mi>g</mi></mrow></math> : Verbal and performance IQ as predictors of socio-political attitudes.

Intelligence·2025
Same author

Characterization of the safety profile of trastuzumab deruxtecan by dose: a pooled analysis across DESTINY studies.

The oncologist·2025

Area of Science:

  • Oncology
  • Neuroscience
  • Pharmacology

Background:

  • Microtubule-stabilizing agents (MTSAs), such as taxanes and epothilones, are vital chemotherapeutics.
  • MTSA-based chemotherapy frequently leads to peripheral neuropathy, a significant adverse effect impacting up to 30% of patients.
  • MTSA-induced neuropathy typically resolves post-treatment but necessitates careful management.

Purpose of the Study:

  • To review the incidence, presentation, and management of microtubule-stabilizing agent-induced neuropathy.
  • To highlight the importance of clinical evaluation in assessing MTSA-induced neuropathy.
  • To identify future research directions for understanding and mitigating MTSA-induced neuropathy.

Main Methods:

  • Literature review focusing on MTSA-induced neuropathy.

Related Experiment Videos

  • Analysis of clinical data regarding incidence and severity.
  • Examination of current and potential assessment techniques.

    • Main Results:

    • Taxane-induced sensory neuropathy is the most studied form, more prevalent with paclitaxel than docetaxel.
    • Neuropathy incidence correlates with MTSA dose, treatment schedule, and infusion duration.
    • Clinical evaluation remains the gold standard for assessing MTSA-induced neuropathy.

    Conclusions:

    • Early recognition and supportive care are paramount for preventing and managing MTSA-induced neuropathy.
    • Further research is needed to elucidate mechanisms, develop preclinical models, and evaluate neuroprotective agents.
    • Improved grading systems and evaluation methods are essential for future clinical trials.